Search results
Results from the WOW.Com Content Network
Taking medications like blood pressure and lipid-lowering drugs for more than 5 years is associated with a lower incidence of dementia, a new study has found. ... which prevent blood clots by ...
[4] [5] [6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non-valvular atrial fibrillation (AF) who have other risk factors, and prevent blood clots after routine knee and hip replacement surgery. [2] [3] [7]
Heparin, a form of heparan sulfate used since the 1930s to prevent blood clots, does not enter the brain, but researchers speculate it could delay Alzheimer’s by disrupting ApoE-HSPG interactions.
Brain ischemia has been linked to a variety of diseases or abnormalities. Individuals with sickle cell anemia, compressed blood vessels, ventricular tachycardia, plaque buildup in the arteries, blood clots, extremely low blood pressure as a result of heart attack, and congenital heart defects have a higher predisposition to brain ischemia in comparison to the average population.
Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. [10] [11] [8] It is taken by mouth. [10] [8] Common side effects include headache, constipation, sleepiness, and dizziness. [10] [11] Severe side effects may include blood clots, psychosis, and heart ...
Medications for high blood pressure are used to prevent pre-stroke dementia. [19] These medications include angiotensin converting enzyme inhibitors, diuretics, calcium channel blockers, sympathetic nerve inhibitors, angiotensin II receptor antagonists or adrenergic antagonists. [medical citation needed]
Antiplatelet drugs are widely used in primary and secondary prevention of thrombotic disease, especially myocardial infarction and ischemic stroke. [1] Antiplatelet therapy with one or more of these drugs decreases the ability of blood clots to form by interfering with the platelet activation process in primary hemostasis. Antiplatelet drugs ...
Infusion-related reactions, skin reactions, hypomagnesaemia, hypocalcaemia, hypokalaemia, blood clots, interstitial lung disease and aseptic meningitis. Denosumab: SC: RANKL inhibitor. Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies